CIBC Asset Management Inc Sells 93,491 Shares of Kenvue Inc. $KVUE

CIBC Asset Management Inc reduced its position in Kenvue Inc. (NYSE:KVUE) by 22.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 318,171 shares of the company’s stock after selling 93,491 shares during the quarter. CIBC Asset Management Inc’s holdings in Kenvue were worth $5,164,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. NBT Bank N A NY lifted its holdings in shares of Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after acquiring an additional 1,006 shares during the period. Salomon & Ludwin LLC acquired a new stake in Kenvue in the 3rd quarter valued at $25,000. Trust Co. of Vermont grew its position in Kenvue by 266.8% in the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares during the period. New England Capital Financial Advisors LLC grew its position in Kenvue by 81.4% in the third quarter. New England Capital Financial Advisors LLC now owns 2,563 shares of the company’s stock valued at $42,000 after acquiring an additional 1,150 shares during the period. Finally, First Pacific Financial bought a new position in shares of Kenvue during the second quarter valued at $54,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Buying and Selling

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The stock was purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This trade represents a 13.27% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.17% of the stock is currently owned by insiders.

Kenvue Stock Performance

KVUE stock opened at $17.50 on Wednesday. The company has a 50 day moving average price of $17.10 and a 200 day moving average price of $18.08. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a market capitalization of $33.52 billion, a PE ratio of 23.33 and a beta of 0.60.

Kenvue (NYSE:KVUE) last released its earnings results on Monday, November 3rd. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period last year, the firm earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on KVUE shares. Barclays upped their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. The Goldman Sachs Group decreased their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research note on Thursday, October 2nd. UBS Group cut their target price on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research note on Wednesday, October 8th. JPMorgan Chase & Co. decreased their price target on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Finally, Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.